# Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC

> **NCT04875585** · PHASE2 · RECRUITING · sponsor: **Medical University Innsbruck** · enrollment: 33 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** neoadjuvant therapy with Pembrolizumab/Lenvatinib
- **PROCEDURE:** Surgery
- **DRUG:** Adjuvant Treatment Phase

## Key facts

- **NCT ID:** NCT04875585
- **Lead sponsor:** Medical University Innsbruck
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-12
- **Primary completion:** 2023-12
- **Final completion:** 2027-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2022-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04875585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04875585, "Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04875585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*